We present a Merkel-cell carcinoma patient nephropathy, undergoing haemodialysis twice weekly developed a left cheek tumour in April 1994. She with chronic renal failure requiring haemodialysis and evaluate the pharmacokinetics of carboplatin and eto-exhibited a 30×33 mm, hemispherical, hard, bright red tumour. There was no palpable cervical lymph-poside during haemodialysis. The area under the concentration-time curve of carboplatin was increased by adenopathy. Routine laboratory findings were as follows: blood urea nitrogen, 128 mg/dl; creatinine, prolonging the interval between administration and haemodialysis. However, that of etoposide was not 7.6 mg/dl; creatinine clearance, 1.9 ml/m2/min; lactate dehydrogenase, 305 IU/l; fasting glucose, 255 mg/dl; changed. Carboplatin showed good membrane permeability in haemodialysis, while etoposide showed no haemoglobin A1c, 7.5%; red blood cell, 231×106/ml; white blood count, 4690/ml; haemoglobin, 8.0 g/dl; permeability. In conclusion, the pharmacokinetics of carboplatin could be controlled by haemodialysis and haematocrit, 21.3%; platelet count, 12.7×104/ml. A biopsy specimen revealed Merkel-cell carcinoma. the interval between chemotherapy and haemodialysis. However, the pharmacokinetics of etoposide were not Neither metastatic lesions nor any other primary lesions were detected by gallium scintigram or com-affected.
Introduction eyelid, wide local excision could not be done. After healing of the surgical lesion, the patient received Merkel-cell carcinoma is a rare aggressive skin cancer combination chemotherapy with carboplatin 150 mg [1 ] . Recent reports reveal that this tumour is associand etoposide 50 mg (on day 1 ) on two occasions ( 30 ated, with frequent locoregional recurrence and early May and 12 July 1994). The carboplatin and etoposide metastatic spread [2,3].
were reconstituted in 100 ml saline and administrated Although combination of carboplatin (CBDCA) and simultaneously for 30 min. etoposide has been found to be an effective therapy for Merkel-cell carcinoma [4] , there are few reports on the pharmacokinetics of carboplatin and etoposide in haemodialysis patients. We present a Merkel-cell Haemodialysis carcinoma patient with chronic renal failure requiring Following the first course of chemotherapy, haemodiahaemodialysis (HD) and discuss the pharmacokinetics lysis was performed 1 h after the administration of of both drugs during haemodialysis in a Merkel-cell both drugs, and following the second course, haemocarcinoma patient with renal failure. dialysis was performed 2 h after administration, using a cellulose-triacetate dialyser (FB-110U, NIPRO). The patient was dialysed for 4 h using a bicarbonate-based
Case report
dialysate with a flow rate of 500 ml/min, and was given a continuous infusion of heparin as an anticoagulant. A 67-year-old woman (height 149 cm, body-weight Blood flow was maintained at 130-150 ml/min. Fluid 41.5 kg) with chronic renal failure due to diabetic removal rate was programmed to attain a dry weight (41.5 kg). Haemodialysis were performed by a tempor-from the femoral vein and dialysed, then returned via Result the median cubital vein.
In the first course of chemotherapy, AUC and plasma concentration of free platinum at the end of the infusion were 4.6 minΩmg/ml and 11 700 ng/ml, and Blood samples those of etoposide were 5.0 minΩmg/ml and 6.7 mg/ml respectively ( Figure 1 ). In the second course, AUC Blood samples were taken from the median cubital and plasma concentration of free platinum at the end vein before drug administration at 30 min, 12, 24, and of the infusion were 4.8 minΩmg/ml and 11 500 ng/ml, 72 h after the drugs. Just after starting haemodialysis, and those of etoposide were 4.9 minΩmg/ml and 2 h after starting haemodialysis, and just before fin-9.2 mg/ml respectively ( Figure 2) . During haemo-ishing haemodialysis, blood samples were taken from dialysis following each course, the concentration of not only the arterial but also the venous line of the carboplatin in the venous line was decreased to haemodialysis circuit. approximately 10% of that in the arterial line. However, the concentration of etoposide in the venous line was almost equal to that in the arterial line.
Drug analysis
Neither metastatic lesions nor recurrence were detected by gallium scintigram and computed tomographic scan The specimens were centrifuged immediately at 3000 in August 1995. r.p.m. at 4°C for 20 min. The a part of supernatant was frozen at −20°C for the measurement of etoposide concentration. The rest was filtrated using a centrifuge filter (Centrifree, Amicon) and then centrifuged for Discussion 20 min at 4°C, and frozen for determination of the free platinum level. Carboplatin-derived free-platinum was determined by flameless atomic absorption spec-We chose carboplatin for this patient with renal insufficiency using the dose determined in previous trophotometry using a Spectr AA 40 (Barian). Etoposide was quantified by a high-performance liquid studies [5,6]. Since free platinum has shown cytotoxicity which causes DNA damage [7] and loses its chromatography ( L-4200UV-VIS, Hitachi). The area under the concentration-time curve ( AUC) was estim-ability to bind to protein [8 ], it is important to control the pharmacokinetics of free platinum in chemother-ated using log-trapezoidal approximation. It was postulated that carboplatin and etoposide concentrations apy. Haemodialysis eliminated the free platinum concentration and free platinum showed good permeability rose progressively during continuous drug infusion and that the concentrations of these drugs at the start of in the present study. There is usually a better relationship between the plasma drug concentration or plasma infusion was zero. AUC and the intensity of pharmacodynamic effects controlled by haemodialysis and the interval between than between the drug dose and these effects [9] . In chemotherapy and haemodialysis. the carboplatin regimen, target AUC is 4-5 minΩmg/ml [10 ] . In this study, the AUC was within this concentra-
